New imaging trick could tame radioactive cancer therapy
NCT ID NCT06122610
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This completed Phase 1 study tested whether a PET scan using 64Cu-DOTATATE (Detectnet) can help doctors plan safer doses of Lutathera therapy for people with neuroendocrine tumors. Four participants received both standard Lutathera treatment and extra PET/CT and SPECT/CT scans to compare how well the PET scan predicted radiation doses to tumors and healthy organs. The goal is to reduce side effects by personalizing treatment based on each patient's unique radiation exposure.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
64Cu-DOTATATE (Detectnet) and 177Lu-DOTATATE (Lutathera)
What this could lead to
If successful, this approach could make Lutathera therapy safer by using a PET scan to better predict radiation doses to tumors and healthy organs.
What could go wrong
This was a very small, early-phase study with only 4 participants, so results may not apply broadly. The method is still experimental and not yet proven to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Wisconsin - Madison
Madison, Wisconsin, 53705, United States